Last reviewed · How we verify
NCT07272408
Remote Ischemic Conditioning in Patients Undergoing Primary Percutaneous Coronary Intervention
NA trial testing Remote ischemic conditioning in Remote in 2 participants. Completed in 30 December 2023.
30 December 2023
Quick facts
| Lead sponsor | Helwan University |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 2 |
| Start date | 1 September 2022 |
| Primary completion | 30 December 2023 |
| Estimated completion | 30 December 2023 |
| Sites | 1 location across Egypt |
Drugs / interventions tested
- Remote ischemic conditioning
- Normal primary percutaneous coronary intervention
Conditions studied
- Remote — all drugs for Remote →
- Ischemic Conditioning — all drugs for Ischemic Conditioning →
- Primary Percutaneous Coronary Intervention — all drugs for Primary Percutaneous Coronary Intervention →
Sponsor
Helwan University
Who can join
Adults 18 to 75, any sex, with Remote or Ischemic Conditioning. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study aimed to detect the effects of remote ischemic conditioning on infarct size, global contractility, morbidity, mortality, and renal function in patients undergoing primary percutaneous coronary intervention.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT07272408
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Remote ischemic conditioning
Trials testing the same drug.
- NCT03484936 — Safety and Efficacy of Remote Ischemic Conditioning in Patients With Spontaneous Intracerebral Hemorrhage · NA · not yet recruiting
- NCT07412249 — Remote Ischemic Conditioning Plus Stenting for Symptomatic Carotid Artery Stenosis · NA · recruiting
- NCT03669653 — Safety and Efficacy of Remote Ischemic Conditioning in Patients With Acute Ischemic Stroke · NA · not yet recruiting
- NCT06702644 — Safety and Efficacy of Remote Ischemic Conditioning in Patients with Chronic Internal Carotid Artery Occlusion Receiving · NA · not yet recruiting
- NCT06171334 — Remote Ischemic Conditioning in PPMS · NA · not yet recruiting
Other Helwan University trials
Trials by the same sponsor.
- NCT07342361 — Using Retrograde Intrarenal Surgery for Managing Staghorn Renal Stones. · NA · recruiting
- NCT06786507 — A Direct Head-to-head Comparison of Ustekinumab with Infliximab for the Treatment of Ulcerative Colitis · not yet recruiting
- NCT06535529 — Acetazolamide Versus Dapagliflozin in Acute Decompensated Heart Failure Patients · Phase 3 · recruiting
- NCT07416331 — Impact Of Using LevosemidanVersus DobutamineOn Right Ventricular Function In AdultPatients Undergoing Elective Valve Rep · completed
- NCT06884995 — Correlation of Weight Loss With Residual Gastric Volume and Shape on Computerized Tomography in Patients Undergoing Slee · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07272408 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Helwan University
- Last refreshed: 9 December 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07272408.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing